Authors

Latest:

Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies

Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.

Natasha Kwendakwema, MD

Latest:

Dr Kwendakwema on the Effects of Financial Toxicity on Treatment Costs in Patients With Cancer

Natasha Kwendakwema, MD, discusses findings from a study on the effects of adverse financial events on treatment costs at the end of life and health care utilization in patients with cancer.

Marios Giannakis, MD, PhD

Latest:

Dr Giannakis on the Initial Efficacy of CGX1321 With or Without Pembrolizumab in GI Cancers

Marios Giannakis, MD, PhD, discusses preliminary efficacy data from a phase 1 study of CGX1321 with or without pembrolizumab in advanced gastrointestinal tumors.

Heather Moore, Pharm D

Latest:

Best Practices in Managing Patients on Capivasertib

Panelists discuss the key advice they would offer to fellow physicians, nurse practitioners, advanced practice providers, and pharmacists involved in the care of patients on capivasertib, emphasizing best practices for patient management and communication.

John Paul Diaz, MD

Latest:

Dr Diaz on the Evolution of Precision Medicine in Cervical Cancer

John Paul Diaz, MD, discusses the evolving use of precision medicine approaches in cervical cancer management.

Ravi Munver, MD

Latest:

Dr. Munver on the Approval of Mitomycin Gel in Urothelial Cancer

Ravi Munver, MD, discusses the approval of mitomycin gel in urothelial cancer.

James K. McCloskey, MD, John Theurer Cancer Center

Latest:

The Future of Lower-Risk MDS: Closing Thoughts and Unmet Needs

Panelists discuss how community oncologists can apply key takeaways from this clinical scenario in their practice, emphasizing the importance of collaborating with academic clinicians for optimal patient identification and treatment selection in the evolving landscape of lower-risk MDS management.

Aditya Bardia, MD, MPH

Latest:

Dr Bardia on the FDA Approval of T-DXd for HER2-Low/-Ultralow Metastatic Breast Cancer

Aditya Bardia, MD, MPH, FASCO, discusses the FDA approval of T-DXd for patients with pretreated HER2-low and -ultralow metastatic breast cancer.

Shawnta Anakwah, MD

Latest:

The Future of Advanced Renal Cell Carcinoma Management

Drs Sumeet Bhatia and Eric Jonasch highlight unmet needs in advanced renal cell carcinoma and share clinical pearls.

Brian Czerniecki, MD, PhD

Latest:

Dr. Czerniecki on the Benefit of Tucatinib in HER2+ Breast Cancer and Brain Metastases

Brian Czerniecki, MD, PhD, discusses the benefit of tucatinib in patients with HER2-positive breast cancer and brain metastases.

Domenech Asbun, MD

Latest:

Mapping Progress in Pancreatic Cancer Surgery: Leveraging New Technology

In this last episode of OncChats: Mapping Progress Made in Pancreatic Cancer Surgery, Horacio J. Asbun, MD, and Domenech Asbun, MD, explain how augmented reality or artificial intelligence may be utilized to improve outcomes for patients with pancreatic cancer who are undergoing surgical procedures.

Salman Fazal, MD, West Penn Hospital

Latest:

Targeted Therapy in Blastic Plasmacytoid Dendritic Cell Neoplasm

Michael R. Shafique, MD

Latest:

Dr. Shafique on the Goal of the CLASSICAL-Lung Trial With Pepinemab/Avelumab in NSCLC

Michael R. Shafique, MD, discusses the dose escalation and expansion of pepinemab in the phase 1b/2, single arm, first-in-human, CLASSICAL-Lung study in advanced non-small cell lung cancer.

Neville E. Sanjana, PhD

Latest:

Dr. Sanjana on the Use of Whole-Exome Sequencing to Predict Immunotherapy Response in Advanced Tumors

Neville E. Sanjana, PhD, discusses a study on the predictive utility of the Cancer Immunotherapy Response CLassifiEr in advanced-stage cancers.

Sarah S. Lee, MD

Latest:

Dr. Lee on Treatment Considerations in Smoldering Multiple Myeloma

Sarah S. Lee, MD, discusses treatment considerations in smoldering multiple myeloma.

Gabe Mannis, MD

Latest:

MRD Testing and the Role of Revumenib in Treatment Response

Panelists discuss the role of minimal residual disease (MRD) testing in acute monocytic leukemia (AML), key findings from the Australasian Leukaemia and Lymphoma Group (ALLG) AMLM26 INTERCEPT study on revumenib, and how the efficacy of revumenib in achieving MRD negativity in NPM1-mutated AML informs future MRD-guided treatment strategies, including the potential integration of menin inhibitors into standard AML relapse prevention protocols.

Pooja Phull, MD

Latest:

Dr Phull on the Efficacy and Safety of Cilta-Cel vs Ide-Cel in R/R Multiple Myeloma

Pooja Phull, MD, discusses the use of ciltacabtagene autoleucel and idecabtagene vicleucel in R/R multiple myeloma.

Monica D. Mead, MD

Latest:

Dr Mead on Unanswered Questions in the Treatment of MCL

Monica D. Mead, MD, discusses the importance of addressing unanswered questions in the treatment of patients with mantle cell lymphoma.

Kayla Freeman, DNP, APRN, FNP-C

Latest:

Closing Thoughts on Evolving Antibody-Drug Conjugate Landscape

The expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.

Brian Gastman, MD, Cleveland Clinic

Latest:

Dr Gastman on Exploratory Biomarker Analysis of the Checkmate76K Trial in Stage IIB/C Melanoma

Brian Gastman, MD, discusses results from a biomarkers analysis of patients with stage IIB/C melanoma in the phase 3 CheckMate76K trial.